Get the Stockscreener App
5.38
0.94%
0.05
After Hours:
5.38
Design Therapeutics Inc stock is traded at $5.38, with a volume of 112.40K.
It is up +0.94% in the last 24 hours and up +13.26% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$5.33
Open:
$5.32
24h Volume:
112.40K
Relative Volume:
0.44
Market Cap:
$303.49M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-4.0149
EPS:
-1.34
Net Cash Flow:
$-58.82M
1W Performance:
+0.56%
1M Performance:
+13.26%
6M Performance:
+33.50%
1Y Performance:
+127.97%
1-Day Range:
$5.245
$5.4437
1-Week Range:
$5.21
$5.615
52-Week Range:
$1.96
$6.91
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Almitas Capital LLC Has $4.20 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Frazier Life Sciences Management L.P. Takes Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Wall Street SWOT: Design Therapeutics stockInnovative approach in genetic disorder treatment - Investing.com
(DSGN) On The My Stocks Page - Stock Traders Daily
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock - Yahoo Finance
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming - The Bakersfield Californian
Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles - Business Wire
Halozyme Therapeutics And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
How to interpret Design Therapeutics Inc (DSGN)’s stock chart patterns - US Post News
Friedreich’s Ataxia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024-2034, estimated DelveInsight - Barchart
Initial in vivo validation of novel cancer therapeutics using AI - Drug Target Review
Designer brands director sells $145,640 in company stock - Investing.com
Progressive Ataxia And Weakness Disorders Market Segments, Drivers, Restraints, And Trends For 2024-2033 - EIN News
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day - Yahoo Finance
Designer Brands Inc’s latest rating changes from various analysts - Knox Daily
Short Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Decreases By 6.9% - MarketBeat
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - StockTitan
Let's Design a Trade Strategy on This Short-Squeezed, Low-Priced Stock - TheStreet
Financial Snapshot: Analyzing Designer Brands Inc (DBI)’s Key Ratio Metrics - The Dwinnex
Designer Brands Inc (NYSE:DBI) stock: You might be surprised - US Post News
Check Out Designer Brands Inc (DBI)’s Trade Data Rather Than the Analysts’ Views - SETE News
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
Acadian Asset Management LLC Has $1.95 Million Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Acadian Asset Management LLC Has $2.03 Million Stock Holdings in Geospace Technologies Co. (NASDAQ:GEOS) - Defense World
DSGN’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Analyzing DSGN’s price-to-book ratio for the last quarter - US Post News
DSGN stock soars to 52-week high, touches $5.52 - Investing.com
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - Marketscreener.com
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - StockTitan
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 4.4% - MarketBeat
Design Therapeutics Inc (DSGN) stock analysis: A comprehensive overview - US Post News
A new trading data show Design Therapeutics Inc (DSGN) is showing positive returns. - SETE News
Design Therapeutics, Inc. (NASDAQ:DSGN) Sees Large Drop in Short Interest - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Sees Large Drop in Short Interest - MarketBeat
North America Rare Disease Therapeutics Market Size, - GlobeNewswire
Psilera receives positive preclinical in vivo data for frontotemporal dementia (FTD) candidate, PSIL-006 - BioSpace
Psilera receives positive preclinical in vivo data for frontotemporal dementia (FTD) candidate, PSIL-006 - StreetInsider.com
Ocuphire Pharma (NASDAQ:OCUP) Stock Quotes, Forecast and News Summary - Benzinga
Design Therapeutics stock soars to 52-week high of $5.28 By Investing.com - Investing.com Australia
Design Therapeutics stock soars to 52-week high of $5.28 By Investing.com - Investing.com Canada
Design Therapeutics stock soars to 52-week high of $5.28 - Investing.com
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet - Yahoo Finance
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet - Nasdaq
Recent Insider Activity Could Benefit Design Therapeutics Inc (DSGN) - Knox Daily
Friedreich’s Ataxia Drugs Market is Projected to Reach US$ 3.49 Billion by 2034 | Fact.MR Report - GlobeNewswire
Friedreich’s Ataxia Drugs Market is Projected to Reach US$ 3.49 Billion by 2034 | Fact.MR Report - ForexTV.com
DSGN’s Q2 earnings predictions: What the experts say - US Post News
Vanguard Group Inc. Reduces Position in LL Flooring Holdings, Inc. (NYSE:LL) - Defense World
Vanguard Group Inc. Acquires 11,200 Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Price T Rowe Associates Inc. MD Makes New $45,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Global Access to Biotherapeutics | JustEvotec Biologics - Evotec
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):